Recent News

• 08.07.2025 - Rani Therapeutics Reports Second Quarter 2025 Financial Results; Provides Corporate Update
• 08.07.2025 - Rani Therapeutics Reports Second Quarter 2025 Financial Results; Provides Corporate Update
• 07.15.2025 - Rani Therapeutics Holdings, Inc. Announces Pricing of $3.0 Million Registered Direct Offering
• 07.15.2025 - Rani Therapeutics Holdings, Inc. Announces Pricing of $3.0 Million Registered Direct Offering
• 07.14.2025 - Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous Delivery
• 07.14.2025 - Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous Delivery

Recent Filings

• 08.07.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.07.2025 - EX-99.1 EX-99.1
• 08.07.2025 - 8-K Current report
• 08.05.2025 - 4 Statement of changes in beneficial ownership of securities
• 07.23.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 07.17.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 07.16.2025 - 8-K Current report
• 07.16.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 07.11.2025 - EFFECT Notice of Effectiveness
• 07.11.2025 - 424B5 Prospectus [Rule 424(b)(5)]